Neurogene Inc. (NASDAQ: NGNE) shares began Wednesday down slightly. The company, a clinical-stage concern founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, said its management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference, Tuesday, October 14 at 7:00 a.m. ET
A webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time.
“The mission of Neurogene,” said this morning’s news release, “is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile.
“The Company’s novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston.”
Shares in NGNE off 30 cents, or 1.3%, to $23.17.
